Real-world experience with belimumab in lupus nephritis: insights from the Spanish cohort

Ana Huerta, Paula López-Sánchez, Eduardo Martínez, Luis F. Quintana, Adoración Martín-Gómez, Vanessa Lopes, Cristina Rabasco, Jorge Alberto Rodriguez, Celia Rodriguez, Alba Temprado, Manuel Lopez-Mendoza, Francisco Jose Borrego, Sara Afonso, Antolina Rodriguez, Loreto Fernandez, Maria Gago, Maria del Carmen Prados, Olga Gracia, Milagros Sierra, Marina Sánchez-Agesta, Javier Carbayo, Fernando Hadad, Ana Romera, Roger Cox, Jose Maria Mora, Begoña Rivas, Juan Fernandez-Solis, Francisco Gomez-Preciado, Maria Teresa Mora, Eva Marquez, Mar Espino, Carmen Larramendi, Mireia Lopez-Corbeto, Adriana Devolder-Nicolau, Adriana Puente-Garcia, Amir Shabaka, Sara Gonzalez, Carmen Martin, Carmen Mon, Ana Tato, Daniel Villa, Maria Galindo, Lucia Martin-Testillano, Jose Portolés, Enrique Morales

Open source

DOI: 10.3389/fimmu.2026.1897450
Published: 2026-08-25
Container: Frontiers in Immunology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2026.1897450,
  title = {Real-world experience with belimumab in lupus nephritis: insights from the Spanish cohort},
  author = {Ana Huerta and Paula López-Sánchez and Eduardo Martínez and Luis F. Quintana and Adoración Martín-Gómez and Vanessa Lopes and Cristina Rabasco and Jorge Alberto Rodriguez and Celia Rodriguez and Alba Temprado and Manuel Lopez-Mendoza and Francisco Jose Borrego and Sara Afonso and Antolina Rodriguez and Loreto Fernandez and Maria Gago and Maria del Carmen Prados and Olga Gracia and Milagros Sierra and Marina Sánchez-Agesta and Javier Carbayo and Fernando Hadad and Ana Romera and Roger Cox and Jose Maria Mora and Begoña Rivas and Juan Fernandez-Solis and Francisco Gomez-Preciado and Maria Teresa Mora and Eva Marquez and Mar Espino and Carmen Larramendi and Mireia Lopez-Corbeto and Adriana Devolder-Nicolau and Adriana Puente-Garcia and Amir Shabaka and Sara Gonzalez and Carmen Martin and Carmen Mon and Ana Tato and Daniel Villa and Maria Galindo and Lucia Martin-Testillano and Jose Portolés and Enrique Morales},
  year = {2026},
  journal = {Frontiers in Immunology},
  doi = {10.3389/fimmu.2026.1897450},
  url = {https://doi.org/10.3389/fimmu.2026.1897450}
}

RIS

TY  - JOUR
TI  - Real-world experience with belimumab in lupus nephritis: insights from the Spanish cohort
AU  - Ana Huerta
AU  - Paula López-Sánchez
AU  - Eduardo Martínez
AU  - Luis F. Quintana
AU  - Adoración Martín-Gómez
AU  - Vanessa Lopes
AU  - Cristina Rabasco
AU  - Jorge Alberto Rodriguez
AU  - Celia Rodriguez
AU  - Alba Temprado
AU  - Manuel Lopez-Mendoza
AU  - Francisco Jose Borrego
AU  - Sara Afonso
AU  - Antolina Rodriguez
AU  - Loreto Fernandez
AU  - Maria Gago
AU  - Maria del Carmen Prados
AU  - Olga Gracia
AU  - Milagros Sierra
AU  - Marina Sánchez-Agesta
AU  - Javier Carbayo
AU  - Fernando Hadad
AU  - Ana Romera
AU  - Roger Cox
AU  - Jose Maria Mora
AU  - Begoña Rivas
AU  - Juan Fernandez-Solis
AU  - Francisco Gomez-Preciado
AU  - Maria Teresa Mora
AU  - Eva Marquez
AU  - Mar Espino
AU  - Carmen Larramendi
AU  - Mireia Lopez-Corbeto
AU  - Adriana Devolder-Nicolau
AU  - Adriana Puente-Garcia
AU  - Amir Shabaka
AU  - Sara Gonzalez
AU  - Carmen Martin
AU  - Carmen Mon
AU  - Ana Tato
AU  - Daniel Villa
AU  - Maria Galindo
AU  - Lucia Martin-Testillano
AU  - Jose Portolés
AU  - Enrique Morales
PY  - 2026
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1897450
UR  - https://doi.org/10.3389/fimmu.2026.1897450
ER  -

APA

Huerta, A., López-Sánchez, P., Martínez, E., Quintana, L. F., Martín-Gómez, A., Lopes, V., Rabasco, C., Rodriguez, J. A., Rodriguez, C., Temprado, A., Lopez-Mendoza, M., Borrego, F. J., Afonso, S., Rodriguez, A., Fernandez, L., Gago, M., Prados, M. D. C., Gracia, O., Sierra, M., Sánchez-Agesta, M., Carbayo, J., Hadad, F., Romera, A., Cox, R., Mora, J. M., Rivas, B., Fernandez-Solis, J., Gomez-Preciado, F., Mora, M. T., Marquez, E., Espino, M., Larramendi, C., Lopez-Corbeto, M., Devolder-Nicolau, A., Puente-Garcia, A., Shabaka, A., Gonzalez, S., Martin, C., Mon, C., Tato, A., Villa, D., Galindo, M., Martin-Testillano, L., Portolés, J., & Morales, E. (2026). Real-world experience with belimumab in lupus nephritis: insights from the Spanish cohort. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1897450

Source records

crossref · retrieved 2026-11-06T10:01:08.121Z